Alnylam Going After Alexion's Soliris In PNH, Eyes Roche In Hemophilia
This article was originally published in The Pink Sheet Daily
Executive Summary
At an investor day, the RNAi firm outlined Phase I programs in paroxysmal nocturnal hemoglobinuria, hemophilia and hepatic porphyria, and said it is using a de-risked drug development methodology.